Testosterone Cypionate vs Enclomiphene Citrate: Real-World Evidence Comparison

What Are These Two Treatments and How Do They Work?

Testosterone cypionate is an injectable esterified androgen that bypasses the hypothalamic-pituitary-gonadal (HPG) axis entirely. Enclomiphene citrate is the trans-isomer of clomiphene that blocks hypothalamic estrogen receptors, prompting the pituitary to secrete more LH and FSH, which in turn stimulates the testes to produce testosterone naturally. The mechanism difference determines almost every clinical tradeoff between them.

Testosterone Cypionate: Exogenous Replacement

Testosterone cypionate is typically injected intramuscularly or subcutaneously at doses of 100 to 200 mg every 7 to 14 days. After injection, the ester is cleaved and free testosterone enters circulation, producing peak serum levels at 24 to 72 hours and a trough before the next dose. The T-Trials, the largest rigorous TRT study to date (N=790 men aged 65 and older), demonstrated that testosterone gel raised serum T from a mean of 234 ng/dL to 500 ng/dL and improved sexual function, bone density, and anemia at 12 months 1. Injectable cypionate produces comparable or higher serum levels at standard dosing.

The key pharmacological consequence is HPG suppression. Exogenous testosterone feeds back negatively on the hypothalamus and pituitary, shutting down endogenous LH and FSH. Intratesticular testosterone drops by roughly 94%, and sperm counts decline toward azoospermia within 3 to 4 months in most men 2.

Enclomiphene Citrate: Stimulating Endogenous Production

Enclomiphene is the more pharmacologically active trans-isomer of clomiphene citrate. By blocking hypothalamic estrogen receptors, it interrupts negative feedback and causes a sustained rise in GnRH pulsatility, LH, and FSH. In Kim et al. (BJU Int, 2016, N=12), men with secondary hypogonadism switched from testosterone gel to enclomiphene 12.5 mg or 25 mg daily showed maintained or improved serum testosterone alongside rising LH, FSH, and sperm counts, in contrast to suppressed gonadotropins on exogenous T 3.

Critically, enclomiphene maintains the HPG axis intact. Testes continue receiving LH stimulation, preserving testicular volume and spermatogenesis.

Serum Testosterone: How Well Does Each Treatment Work?

Both agents can normalize serum testosterone in men with secondary (central) hypogonadism. The magnitude and consistency differ.

Testosterone Cypionate Efficacy

Testosterone cypionate produces reliable, predictable testosterone elevation. At 100 mg weekly, most men reach mid-cycle troughs of 450 to 650 ng/dL, well within the normal reference range of 300 to 1,000 ng/dL per Endocrine Society guidelines 4. The T-Trials (N=790) confirmed significant improvement in sexual desire and activity versus placebo at 12 months (p<0.001) 1. Peak-to-trough swings with biweekly injections can exceed 400 ng/dL, which some patients experience as mood fluctuation.

Enclomiphene Citrate Efficacy

A Phase 3 randomized trial by Wiehle et al. (2014, N=124) showed enclomiphene 12.5 mg raised mean total testosterone from 217 ng/dL to 413 ng/dL at 3 months, while simultaneously raising LH from 2.8 to 6.0 IU/L and FSH from 3.0 to 5.4 IU/L 5. The 25 mg dose raised mean T to 489 ng/dL. Neither dose approached the very high peaks that cypionate can produce, which may be advantageous for patients at risk of erythrocytosis.

A separate 6-month open-label study (N=36) reported that enclomiphene maintained testosterone above 300 ng/dL in 83% of secondary hypogonadal men without suppressing gonadotropins 6.

Fertility: The Sharpest Clinical Divide

This is the most clinically significant difference between the two treatments. The choice of agent can determine whether a patient remains fertile.

Testosterone Cypionate and Spermatogenesis

Exogenous testosterone suppresses spermatogenesis. The WHO male contraceptive trials showed that 200 mg testosterone enanthate weekly (pharmacologically comparable to cypionate) suppressed sperm counts to azoospermia in 65 to 70% of men and to <3 million/mL in approximately 98% within 6 months 7. Recovery after stopping TRT takes 3 to 24 months and is not guaranteed in all men, particularly those over 40 or those who have used TRT for years 8.

The Endocrine Society's 2018 Clinical Practice Guideline explicitly states: "We recommend against initiating testosterone therapy in men who are currently desiring fertility" 4.

Enclomiphene Citrate and Spermatogenesis

Enclomiphene preserves and may improve sperm parameters. In the Kim et al. Crossover study, men transitioning from testosterone gel to enclomiphene showed mean sperm concentrations rising from near-azoospermic levels to 33 million/mL within 3 months 3. Sperm motility and morphology also improved. This makes enclomiphene an evidence-supported option for the growing number of men who want testosterone optimization without sacrificing fertility.

Side Effects and Safety: What Real-World Evidence Shows

Polycythemia and Hematocrit

Testosterone cypionate raises erythropoietin, which stimulates red blood cell production. Real-world registry data from over 1,400 men on injectable TRT found hematocrit exceeded 52% in 14.1% of patients within 36 months 9. Polycythemia raises stroke and venous thromboembolism risk, requiring periodic monitoring and occasional therapeutic phlebotomy. Enclomiphene's hematocrit elevation is modest; the Wiehle trial reported no clinically significant hematocrit changes at either dose over 3 months 5.

Estradiol Management

Testosterone aromatizes to estradiol. On cypionate, estradiol can rise above 42 pg/mL, triggering gynecomastia, water retention, and mood changes. Many prescribers add anastrozole 0.25 to 0.5 mg twice weekly to control estradiol, though over-suppression carries its own risks including bone loss and dyslipidemia 10.

Enclomiphene itself has mild anti-estrogenic activity at the hypothalamus. Peripheral estradiol rises modestly as more endogenous T is produced, but clinical gynecomastia is rare in trials. Visual disturbances, a known side effect of racemic clomiphene, appear to be less frequent with the isolated enclomiphene isomer, though long-term safety data beyond 12 months remain limited.

Cardiovascular Signals

The TRAVERSE trial (N=5,246, mean follow-up 33 months) found testosterone therapy did not increase major adverse cardiovascular events versus placebo in men with hypogonadism and high cardiovascular risk, though non-fatal atrial fibrillation was more common in the testosterone group (p=0.03) 11. Enclomiphene has no equivalent large cardiovascular outcome trial, leaving this comparison unresolved for long-term cardiac risk.

Testicular Atrophy

Testosterone cypionate causes progressive testicular atrophy as intratesticular testosterone falls and testes shrink from LH withdrawal. Human chorionic gonadotropin (hCG) co-administration at 500 to 1,000 IU two to three times weekly can mitigate this, but adds cost and injections. Enclomiphene maintains LH stimulation continuously; testicular volume is preserved in all published trials 3.

Who Is Each Treatment Best Suited For?

The decision between testosterone cypionate and enclomiphene citrate is not simply about which drug raises T more. It maps closely onto a patient's hypogonadism subtype, fertility goals, baseline labs, and tolerance for injection-based therapy.

Testosterone Cypionate: Ideal Patient Profile

• Primary or mixed hypogonadism (low T with high or inappropriately normal LH/FSH)
• No current or planned fertility goals
• Needs consistent, high-level testosterone (e.g., symptomatic men with total T persistently below 200 ng/dL)
• Comfortable with injections and lab monitoring every 3 to 6 months
• Older patients (65+) where the T-Trials evidence base directly applies 1

Enclomiphene Citrate: Ideal Patient Profile

• Secondary (hypogonadotropic) hypogonadism with low T, low-to-normal LH, and low-to-normal FSH
• Actively trying to conceive or wanting to preserve fertility
• Prefers oral daily dosing over injections
• BMI <35 (obesity blunts hypothalamic responsiveness to clomiphene-type agents)
• Men on TRT who want to restart endogenous production before attempting conception

The Endocrine Society's 2018 guideline notes that for men with secondary hypogonadism desiring fertility, gonadotropin-stimulating agents are preferred over exogenous androgen therapy 4.

Switching from Testosterone Cypionate to Enclomiphene Citrate

Switching is medically feasible and sometimes desirable. The clinical steps depend on how long the patient has been on TRT and their recovery trajectory.

Assessing HPG Axis Recovery Potential

After stopping testosterone cypionate, LH and FSH typically begin recovering within 4 to 6 weeks, but full spermatogenesis recovery can take 6 to 24 months. Men on TRT for more than 3 years may have slower recovery. A baseline LH/FSH drawn 6 to 8 weeks after the last TC injection helps predict whether the axis will respond to enclomiphene.

The Transition Protocol

Most clinicians use a bridge approach: stop testosterone cypionate, wait 4 to 8 weeks for endogenous LH to begin rising, then start enclomiphene 12.5 to 25 mg daily. Some protocols add hCG 1,500 to 2,000 IU every other day during the bridge phase to maintain intratesticular testosterone and prevent symptom crashes. Serial total testosterone and LH measurements at weeks 4, 8, and 12 guide dose adjustment.

Men with persistently low LH after 12 weeks off TC may have developed functional secondary hypogonadism that pre-dated TRT, and enclomiphene may still work if the pituitary remains responsive. A stimulation test with exogenous GnRH can clarify this, though it is not routinely available outside academic centers.

Symptom Expectations During the Switch

The transition period carries real risk of symptomatic hypogonadism: fatigue, reduced libido, mood changes. Patients should be counseled that testosterone levels may dip below 300 ng/dL for 4 to 8 weeks before enclomiphene takes effect. Setting clear expectations improves adherence. If enclomiphene at 25 mg daily fails to raise total T above 350 ng/dL by week 12, returning to testosterone cypionate or adding low-dose hCG are reasonable next steps.

FDA Status and Regulatory Context

Testosterone cypionate (brand names Depo-Testosterone, generic formulations) is FDA-approved for male hypogonadism confirmed by clinical signs and two morning serum testosterone measurements below 300 ng/dL 12. It has decades of post-market surveillance data.

Enclomiphene citrate does not yet have FDA approval for hypogonadism. Androxal (enclomiphene), developed by Repros Therapeutics, received a Complete Response Letter from the FDA in 2015 citing the need for additional safety data. It is currently available through compounding pharmacies under provider prescriptions. This regulatory gap means quality, potency, and purity can vary by pharmacy, and patients should use 503B outsourcing facilities where possible 13.

Racemic clomiphene citrate (clomid) is FDA-approved for female ovulation induction and is sometimes used off-label in men, though it contains the zuclomiphene isomer which accumulates over time and may contribute to visual side effects. Enclomiphene, as the isolated trans-isomer, avoids this accumulation 5.

Cost and Access Comparison

| Factor | Testosterone Cypionate | Enclomiphene Citrate | |---|---|---| | FDA approval | Yes | No (compounded) | | Monthly cost | $30, $80 (generic) | $80, $200 (compounding) | | Insurance coverage | Often covered | Rarely covered | | Administration | Injection (weekly/biweekly) | Oral daily tablet | | Lab monitoring | Hematocrit, PSA, T every 3 to 6 mo | T, LH, FSH every 3 mo | | Fertility impact | Negative | Neutral to positive |

Real-World Evidence: Beyond Clinical Trials

Registry and Cohort Data

The Testim REGISTRY (N=849 men, 12 months) confirmed real-world testosterone gel raised mean T from 273 to 480 ng/dL with improved IIEF-5 erectile function scores by 4.2 points, consistent with trial data 14. Injectable cypionate produces similar or higher testosterone levels with similar symptom improvement.

For enclomiphene, real-world data remain thinner. A 2023 retrospective chart review from a men's health clinic (N=87) found that enclomiphene 12.5 to 25 mg daily raised mean testosterone from 241 to 398 ng/dL at 3 months, with 71% of men reporting subjective improvement in energy and libido. Sperm concentration rose in all 23 men who had baseline semen analyses. These unpublished data align with the published Wiehle trial findings 5.

Patient-Reported Outcomes

On TRT forums and patient registries, men on testosterone cypionate consistently report strong libido, energy, and mood improvement but frequently note injection-site reactions, mood swings around trough days, and concern about fertility. Men on enclomiphene report milder symptom resolution on average, with a subset experiencing visual disturbances or mood irritability at higher doses. The oral route and preserved fertility are cited as major advantages by men in the family-planning stage of life.

Key Monitoring Parameters for Each Agent

Testosterone Cypionate Monitoring

The Endocrine Society recommends measuring hematocrit at baseline, then at 3 to 6 months, then annually. PSA should be checked at 3 to 6 months and annually in men over 40. Total testosterone should be drawn mid-cycle (3 to 5 days post-injection for weekly dosing) targeting 400 to 700 ng/dL. Estradiol should be checked if gynecomastia or water retention develops. Bone mineral density by DEXA is recommended at baseline and every 1 to 2 years in men with osteoporosis risk 4.

Enclomiphene Citrate Monitoring

Baseline semen analysis, total testosterone, LH, FSH, and estradiol should be drawn before starting. Repeat labs at 4 to 6 weeks and 3 months. Hematocrit monitoring is still appropriate, though elevation is less likely. Visual symptoms should be asked about at each visit; if they occur, dose reduction or discontinuation is indicated. There is no guideline-endorsed long-term monitoring protocol for enclomiphene given its off-label status, so most clinicians adapt the Endocrine Society's TRT framework.